MCID: URT032
MIFTS: 26

Urethra Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Urethra Adenocarcinoma

Aliases & Descriptions for Urethra Adenocarcinoma:

Name: Urethra Adenocarcinoma 12 14
Adenocarcinoma of the Urethra 12
Urethral Adenocarcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4910
NCIt 47 C6167
UMLS 69 C1336885

Summaries for Urethra Adenocarcinoma

Disease Ontology : 12 An urethra cancer that derives from epithelial cells of glandular origin.

MalaCards based summary : Urethra Adenocarcinoma, also known as adenocarcinoma of the urethra, is related to urethra clear cell adenocarcinoma and colon signet ring adenocarcinoma. An important gene associated with Urethra Adenocarcinoma is FNDC3B (Fibronectin Type III Domain Containing 3B), and among its related pathways/superpathways is Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex. The drugs Fentanyl and Adjuvants, Anesthesia have been mentioned in the context of this disorder. Related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Urethra Adenocarcinoma

Graphical network of the top 20 diseases related to Urethra Adenocarcinoma:



Diseases related to Urethra Adenocarcinoma

Symptoms & Phenotypes for Urethra Adenocarcinoma

MGI Mouse Phenotypes related to Urethra Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ALK AMACR APP ARID2 ATM FNDC3B
2 mortality/aging MP:0010768 9.23 FNDC3B PAX8 SMAD4 ALK AMACR APP

Drugs & Therapeutics for Urethra Adenocarcinoma

Drugs for Urethra Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Adjuvants, Anesthesia Phase 3
3 Analgesics Phase 3
4 Analgesics, Opioid Phase 3
5 Anesthetics Phase 3
6 Anesthetics, General Phase 3
7 Anesthetics, Intravenous Phase 3
8 Central Nervous System Depressants Phase 3
9 Liver Extracts Phase 3,Phase 1
10 Narcotics Phase 3
11 pancreatic polypeptide Phase 3,Phase 1
12 Peripheral Nervous System Agents Phase 3
13 Cola Nutraceutical Phase 3,Phase 1
14
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
15
Ifosfamide Approved Phase 2 3778-73-2 3690
16
Mechlorethamine Approved Phase 2 51-75-2 4033
17
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
18
nivolumab Approved Phase 2,Phase 1 946414-94-4
19
Fluorouracil Approved Phase 2 51-21-8 3385
20
Gemcitabine Approved Phase 2 95058-81-4 60750
21
Levoleucovorin Approved Phase 2 68538-85-2
22
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
25
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
26
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
27 Piritrexim Investigational Phase 2 72732-56-0
28
Camptothecin Experimental Phase 2 7689-03-4
29 Albumin-Bound Paclitaxel Phase 2,Phase 1
30 Alkylating Agents Phase 2
31 Antimitotic Agents Phase 2,Phase 1
32 Antineoplastic Agents, Alkylating Phase 2
33 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
34 Isophosphamide mustard Phase 2
35 Folic Acid Antagonists Phase 2
36 Vitamin B Complex Phase 2
37 Rubitecan Phase 2
38 topoisomerase I inhibitors Phase 2
39 Topoisomerase Inhibitors Phase 2
40 Anti-Infective Agents Phase 2,Phase 1
41 Immunosuppressive Agents Phase 2,Phase 1
42 Antibodies Phase 2,Phase 1
43 Antibodies, Monoclonal Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Antimetabolites Phase 2
46 Antimetabolites, Antineoplastic Phase 2
47 Antiviral Agents Phase 2
48 Micronutrients Phase 2
49 Nicotinic Acids Phase 2
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show all 26)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma Completed NCT00252941 Phase 1, Phase 2
3 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2
4 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2
5 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
6 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
7 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
8 Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer Recruiting NCT02570919 Phase 2
9 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2
10 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2
11 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Not yet recruiting NCT03170960 Phase 1, Phase 2
12 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2
13 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2
14 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
15 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
16 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
17 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Recruiting NCT02443324 Phase 1
18 Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy Recruiting NCT02976402 Phase 1
19 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1
20 Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants Completed NCT00900276
21 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383
22 Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Completed NCT01526486
23 Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer Recruiting NCT02761889
24 Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer Recruiting NCT02470897
25 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers Recruiting NCT01846520
26 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699

Search NIH Clinical Center for Urethra Adenocarcinoma

Genetic Tests for Urethra Adenocarcinoma

Anatomical Context for Urethra Adenocarcinoma

Publications for Urethra Adenocarcinoma

Articles related to Urethra Adenocarcinoma:

id Title Authors Year
1
Female urethra adenocarcinoma: report of two cases and bibliographic review. ( 25306993 )
2014

Variations for Urethra Adenocarcinoma

Expression for Urethra Adenocarcinoma

Search GEO for disease gene expression data for Urethra Adenocarcinoma.

Pathways for Urethra Adenocarcinoma

Pathways related to Urethra Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 9.97 ATM SMAD4

GO Terms for Urethra Adenocarcinoma

Biological processes related to Urethra Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.43 ALK ATM PAX8
2 ovarian follicle development GO:0001541 9.37 ATM SMAD4
3 branching involved in ureteric bud morphogenesis GO:0001658 9.32 PAX8 SMAD4
4 neuron apoptotic process GO:0051402 9.16 APP ATM
5 female gonad development GO:0008585 8.96 ATM SMAD4
6 kidney development GO:0001822 8.8 PAX8 SMAD4 UPK3A

Sources for Urethra Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....